

Medical Policy Manual **Approved Rev: Do Not Implement until 9/30/26**

Galsulfase (Naglazyme®)

IMPORTANT REMINDER

We develop Medical Policies to provide guidance to Members and Providers. This Medical Policy relates only to the services or supplies described in it. The existence of a Medical Policy is not an authorization, certification, explanation of benefits or a contract for the service (or supply) that is referenced in the Medical Policy. For a determination of the benefits that a Member is entitled to receive under his or her health plan, the Member's health plan must be reviewed. If there is a conflict between the medical policy and a health plan or government program (e.g., TennCare), the express terms of the health plan or government program will govern.

POLICY

INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication

Naglazyme is indicated for patients with Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome). Naglazyme has been shown to improve walking and stair-climbing capacity.

All other indications are considered experimental/investigational and not medically necessary.

DOCUMENTATION

Submission of the following information is necessary to initiate the prior authorization review:

Initial Requests:

- N-acetylgalactosamine-4-sulfatase (arylsulfatase B) enzyme assay or genetic testing results supporting diagnosis.
- **Chart notes or medical records documenting clinical signs and symptoms of disease at baseline (e.g., decreased growth velocity, coarse facial features, skeletal deformities, frequent upper-airway infections, enlarged liver and spleen, hearing loss, joint stiffness, coarse hair).**

Continuation Requests:

- Chart notes documenting a clinically positive response to therapy, which shall include improvement, stabilization, or slowing of disease progression **(e.g., improvement, stabilization, or slowing of disease progression for growth rate, 12-minute walk test, 3-minute stair climb test, urinary glycosaminoglycan (GAG) levels).**

PRESCRIBER SPECIALITIES

This medication must be prescribed by or in consultation with a physician who specializes in the treatment of metabolic disease and/or lysosomal storage disorders.

COVERAGE CRITERIA

Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)



Medical Policy Manual **Approved Rev: Do Not Implement until 9/30/26**

Authorization of 12 months may be granted for treatment of MPS VI (Maroteaux-Lamy syndrome) when **both of the following criteria are met:**

- The diagnosis of MPS VI was confirmed by enzyme assay demonstrating a deficiency of N-acetylgalactosamine-4-sulfatase (arylsulfatase B) enzyme activity or by genetic testing.
- **Member exhibits clinical signs and symptoms of disease at baseline (e.g., decreased growth velocity, coarse facial features, skeletal deformities, frequent upper-airway infections, enlarged liver and spleen, hearing loss, joint stiffness, coarse hair).**

CONTINUATION OF THERAPY

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in the Coverage Criteria section who have a clinically positive response to therapy, which shall include improvement, stabilization, or slowing of disease progression **(e.g., improvement, stabilization, or slowing of disease progression for growth rate, 12-minute walk test, 3-minute stair climb test, urinary glycosaminoglycan (GAG) levels).**

APPLICABLE TENNESSEE STATE MANDATE REQUIREMENTS

BlueCross BlueShield of Tennessee's Medical Policy complies with Tennessee Code Annotated Section 56-7-2352 regarding coverage of off-label indications of Food and Drug Administration (FDA) approved drugs when the off-label use is recognized in one of the statutorily recognized standard reference compendia or in the published peer-reviewed medical literature.

ADDITIONAL INFORMATION

For appropriate chemotherapy regimens, dosage information, contraindications, precautions, warnings, and monitoring information, please refer to one of the standard reference compendia (e.g., the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) published by the National Comprehensive Cancer Network®, Drugdex Evaluations of Micromedex Solutions at Truven Health, or The American Hospital Formulary Service Drug Information).

REFERENCES

1. Naglazyme [package insert]. Novato, CA: BioMarin Pharmaceutical Inc.; September 2024.
2. Akyol, M.U., Alden, T.D., Amartino, H. et al. Recommendations for the management of MPS VI: systematic evidence- and consensus-based guidance. Orphanet J Rare Dis 14, 118 (2019).
3. **Decker C, Yu ZF, Giugliani R, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: Growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. J Pediatr Rehabil Med. 2010;3(2):89-100. doi:10.3233/PRM-2010-0113**

EFFECTIVE DATE

9/30/2026

ID_CHS_2026